TAS-120 (Futibatinib)

Cat. No.: DC11089 Featured
TAS-120 (Futibatinib)
Chemical Structure
1448169-71-8
For research use only. We do not sell to patients.
We match the best price and quality on market.
Email:order@dcchemicals.com  sales@dcchemicals.com
Tel:+86-021-58447131
We are official vendor of:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
More than 5000 active chemicals with high quality for research!
Field of application
TAS-120 is a highly potent and selective irreversible FGFR inhibitor, effective in tumors harboring various FGFR gene abnormalities.
Cas No.: 1448169-71-8
Chemical Name: 1-[(3S)-3-{4-amino-3-[(3,5-dimethoxyphenyl)ethynyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl}pyrrolidin-1-yl]prop-2-en1-one
Synonyms: Futibatinib;TAS120
SMILES: C(N1CC[C@@H](N2C3C(C(C#CC4=CC(OC)=CC(OC)=C4)=N2)=C(N)N=CN=3)C1)(=O)C=C
Formula: C22H22N6O3
M.Wt: 418.457
Purity: >98%
Sotrage: 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Description: TAS-120 (Futibatinib, TAS120) is a highly potent, selective, irreversible pan-FGFR inhibitor with IC50 of 0.9 nM for wt FGFR2; inhibits cancer cell growth in vitro and shows promising activity in human xenografts of FGFR mutation-bearing tumours; TAS-120 inhibits mutant and wild-type FGFR2 with similar IC50 (wild-type FGFR2, 0.9 nM; V565I 1.3 nM; N550H, 3.6 nM; E566G, 2.4 nM) and has shown efficacy in FGFR inhibitor-resistant cell lines.
In Vivo:
In Vitro:
References:
Kinase Assay:
Cell Assay:
Animal Administration:
References:
MSDS
TITLE DOWNLOAD
MSDS_11805_DC11089_1448169-71-8
COA
LOT NO. DOWNLOAD
Cat. No. Product name Field of application
DC11089 TAS-120 (Futibatinib) TAS-120 is a highly potent and selective irreversible FGFR inhibitor, effective in tumors harboring various FGFR gene abnormalities.
DC8418 CH5183284 (Debio-1347) CH5183284 is a selective and orally available FGFR inhibitor with IC50 of 9.3 nM, 7.6 nM, 22 nM, and 290 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively. Phase 1.